Core Insights - Qualigen Therapeutics, Inc. is undergoing a significant transformation, transitioning from a traditional biotechnology company to a decentralized artificial intelligence technology platform under the new name AIxCrypto Holdings, Inc. [4][5][6] - Faraday Future is set to become the majority and controlling shareholder with an estimated 55% direct equity ownership, increasing to approximately 63% when including affiliated stockholders [2][10] - The company will host a renaming and ticker activation ceremony on November 20, 2025, where it will unveil its new business framework, ecosystem architecture, and a three-year development roadmap [4][7][10] Shareholder Approvals - All proposals at the Special Meeting of Stockholders were approved, confirming Faraday Future as the new majority and controlling shareholder [10] - The approved actions include the nomination of a majority of board seats by Faraday Future prior to the renaming event [10] - A subscription agreement was approved for the issuance of 337,432 common shares and 39,943 Series B convertible preferred shares [11] Strategic Transformation - The renaming signifies a strategic shift towards a Web3-driven decentralized AI technology platform, aiming to create a reciprocal strategic enablement dynamic between AIxCrypto and Faraday Future [5][6] - The company is committed to defining itself as a leading gateway to the AI × Web3 era, with a focus on decentralized AI, Web3 asset infrastructure, and intelligent trading systems [6][7][8] - The upcoming ceremony will also introduce the newly structured Board of Directors and the incoming Chairperson [4][10]